174 related articles for article (PubMed ID: 26588333)
1. MAP Kinase Pathways: Molecular Roads to Primary Acral Lentiginous Melanoma.
Fernandes JD; Hsieh R; de Freitas LA; Brandao MA; Lourenço SV; Sangueza M; Nico MM
Am J Dermatopathol; 2015 Dec; 37(12):892-7. PubMed ID: 26588333
[TBL] [Abstract][Full Text] [Related]
2. The CDKN2A and MAP kinase pathways: molecular roads to primary oral mucosal melanoma.
Hsieh R; Nico MM; Coutinho-Camillo CM; Buim ME; Sangueza M; Lourenço SV
Am J Dermatopathol; 2013 Apr; 35(2):167-75. PubMed ID: 23000904
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas.
Takata M; Goto Y; Ichii N; Yamaura M; Murata H; Koga H; Fujimoto A; Saida T
J Invest Dermatol; 2005 Aug; 125(2):318-22. PubMed ID: 16098043
[TBL] [Abstract][Full Text] [Related]
4. TERT amplification but not activation of canonical Wnt/β-catenin pathway is involved in acral lentiginous melanoma progression to metastasis.
Ramani NS; Aung PP; Gu J; Sfamenos S; Sdringola-Maranga C; Nagarajan P; Tetzlaff MT; Curry JL; Ivan D; Diab A; Prieto VG; Hwu WJ; Torres-Cabala CA
Mod Pathol; 2020 Oct; 33(10):2067-2074. PubMed ID: 32404956
[TBL] [Abstract][Full Text] [Related]
5. CSE1L Links cAMP/PKA and Ras/ERK pathways and regulates the expressions and phosphorylations of ERK1/2, CREB, and MITF in melanoma cells.
Lee WR; Shen SC; Wu PR; Chou CL; Shih YH; Yeh CM; Yeh KT; Jiang MC
Mol Carcinog; 2016 Nov; 55(11):1542-1552. PubMed ID: 26331446
[TBL] [Abstract][Full Text] [Related]
6. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
7. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
8. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
9. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C alpha associates with phospholipase D1 and enhances basal phospholipase D activity in a protein phosphorylation-independent manner in human melanoma cells.
Oka M; Kageshita T; Ono T; Goto A; Kuroki T; Ichihashi M
J Invest Dermatol; 2003 Jul; 121(1):69-76. PubMed ID: 12839565
[TBL] [Abstract][Full Text] [Related]
11. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.
Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC
Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
13. Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma.
Cho WC; Wang WL; Milton DR; Ingram DR; Nagarajan P; Curry JL; Ivan D; Lazar AJ; Hwu WJ; Prieto VG; Torres-Cabala CA; Aung PP
Arch Pathol Lab Med; 2021 Jul; 145(7):842-850. PubMed ID: 33053175
[TBL] [Abstract][Full Text] [Related]
14. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
15. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
[TBL] [Abstract][Full Text] [Related]
16. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
17. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
18. Marker Protein Expression Combined With Expression Heterogeneity is a Powerful Indicator of Malignancy in Acral Lentiginous Melanomas.
Cintra Lopes Carapeto F; Neves Comodo A; Germano A; Pereira Guimarães D; Barcelos D; Fernandes M; Landman G
Am J Dermatopathol; 2017 Feb; 39(2):114-120. PubMed ID: 28134728
[TBL] [Abstract][Full Text] [Related]
19. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).
Dwivedi Y; Rizavi HS; Zhang H; Roberts RC; Conley RR; Pandey GN
Int J Neuropsychopharmacol; 2009 Nov; 12(10):1337-54. PubMed ID: 19835659
[TBL] [Abstract][Full Text] [Related]
20. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
